Advertisement

Topics

Merck's antiviral drug meets main goal in late-stage trial

10:41 EDT 19 Oct 2016 | Topix

Oct 19 Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial. Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients.

Original Article: Merck's antiviral drug meets main goal in late-stage trial

NEXT ARTICLE

More From BioPortfolio on "Merck's antiviral drug meets main goal in late-stage trial"

Quick Search
Advertisement